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ABSTRACT
Background: Although recently introduced directional
DBS leads provide control of the stimulation field, pro-
graming is time-consuming.
Objectives: Here, we validate local field potentials
recorded from directional contacts as a predictor of
the most efficient contacts for stimulation in patients
with PD.
Methods: Intraoperative local field potentials were
recorded from directional contacts in the STN of 12
patients and beta activity compared with the results of
the clinical contact review performed after 4 to 7
months.
Results: Normalized beta activity was positively corre-
lated with the contact’s clinical efficacy. The two con-
tacts with the highest beta activity included the most
efficient stimulation contact in up to 92% and that with
the widest therapeutic window in 74% of cases.
Conclusion: Local field potentials predict the most
efficient stimulation contacts and may provide a useful
tool to expedite the selection of the optimal contact for
directional DBS. VC 2017 The Authors. Movement Disor-
ders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder
Society.
Key Words: Parkinson’s disease; deep brain stimula-
tion; directional leads; local field potentials; DBS
programming
A major advance in DBS technology was the intro-
duction of directional DBS leads with segmented con-
tacts and multiple source current steering.1,2 The
middle two levels of conventional ring-contact
DBS electrodes are replaced with three segmented
(noncircular) contacts (Fig. 1A), which allow steering
of the stimulation field. Two intraoperative studies,1,3
a postoperative clinical trial and a case report,4,5 have
reported an increased therapeutic window and efficacy
of directional compared to spherical stimulation.
These advantages are offset by the complexity of pro-
gramming directional DBS. The monopolar contact
review is the crucial initial step and gold standard for the
management of DBS patients6,7 and requires a highly
trained person.8 The use of directional DBS leads implies
testing of a total of 16 stimulation contacts (8/hemi-
sphere), with 12 (6/hemisphere) of them being segment-
ed (Fig. 1A) and requires much more time. Thus, tools
that can expedite programming and optimize the use of
directional electrodes are strongly needed.9
Local field potential (LFP) activity in the beta band
(13-35Hz) has previously been shown to be related to
motor symptoms in Parkinson’s disease (PD) and to
predominantly arise in the motor portion of the
STN.10-12 Importantly, it has also been demonstrated
that the ring contact closest to the beta source is clini-
cally more efficient compared to other contacts.11,13-15
Here, we test the hypothesis that delivery of stimula-
tion in the direction of the highest beta-band activity
in the STN provides the best stimulation effect and
that the LFP may therefore serve as a tool to assist
DBS programming.
Patients and Methods
Twelve PD patients undergoing STN-DBS surgery
were implanted with directional leads (Boston Scientif-
ic, Marlborough, MA; Supplementary Table 1). LFPs
were recorded during surgery from the directional
contacts after each lead was placed in its final position
(Fig. 1B). Normalized beta activity was derived from
each directional contact by normalization of the indi-
vidual beta peak activity by the whole beta band (13-
35Hz). In cases where no beta peak was present, the
low beta band (13-20Hz) was normalized. Monopolar
contact review took place 4 to 7 months postsurgery.
Clinical efficacy (% rigidity improvement/stimulation
current) and therapeutic window (TW) were calculat-
ed for each directional contact and compared with the
corresponding normalized beta activity. Detailed
methods are included in the Supplementary Material.
Results
Relationship Between Beta Activity and
Response to stimulation
In 15 of 19 hemispheres tested, we found a positive
relationship (t185 4.65; P<0.001, one-sample t test)
between normalized beta activity and clinical efficacy
(ranked values: Fig. 1C; absolute nonranked values:
Supplementary Fig. 3). Thus, the higher the relative
beta activity recorded from a specific directional con-
tact, the better its clinical efficacy. In all cases, the
contact with highest beta was consistently one of
those with higher clinical efficacy, and in 12 of 19
cases (63%), it corresponded to the contact with the
highest clinical efficacy. In 7 of 19 cases (36%; hemi-
spheres 13-19), we did not find a clear beta peak, but
despite this, the relationship was similar to those with
a clear peak in the beta band. There was also no dif-
ference in the predictive value of the level and orienta-
tion of the beta peak between those hemispheres with
a beta peak up to 20Hz (52, 3, 5, 6, 7, 10, and 11)
and those hemispheres with a beta peak above 20Hz
(hemispheres 1, 4, 8, 9, and 12). The ring level
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FIG. 1.
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containing the contact with the highest beta activity
was localized in the dorsal STN (ventral STN50;
middle STN54; dorsal STN5 15).
Predictive Value of Beta Activity for the Most
Efficient Stimulation Contact
In Figure 2A, we tested the predictive value of con-
tacts ranked by relative beta power for clinical effica-
cy. This shows that the stimulation contact with the
highest beta activity was able to predict the stimula-
tion contact with the highest clinical efficacy in 63%
of cases. More strikingly, when including the contact
with the second-highest beta activity, the prediction
rose to 84%, and up to 92% if only hemispheres with
a clear beta peak (n5 12) were considered. In con-
trast, conventional clinical testing had only a 17%
likelihood of identifying the most efficient contact if
only one contact was assessed, and a 34% likelihood
if two contacts were assessed. Figure 2B shows that
the mean clinical efficacy of the two contacts with the
highest beta activity was significantly higher
(31.363.2%/mA [milliamperes]) compared to the
mean clinical efficacy (26.16 2.7%/mA) of the
remaining contacts of the same electrode (t185 3.75;
P5 0.0015, paired t test).
Relationship Between Clinical Efficacy and
Therapeutic Window
Another important clinical parameter is the thera-
peutic window, which also includes the side-effect
threshold. Figure 2C shows that the LFP-based strate-
gy identified the contact with the widest therapeutic
window in 42% of cases if only the contact with the
highest beta activity was considered, and in 74% if
the two highest beta contacts were considered. No rel-
evant difference in the predictive value was found
when hemispheres with a clear beta peak were exclu-
sively considered. Additionally, Figure 2D shows that
the mean therapeutic window of the two contacts
with the highest beta activity was significantly higher
(1.4560.27 mA) compared to the mean TW
(0.9660.17 mA) of the remaining contacts of the
same electrode (t1853.11; P50.006, paired t test).
Discussion
In this study, we demonstrate, in a sizeable patient
cohort, that the two segmented contacts of the direc-
tional DBS electrode with maximal STN beta activity
are highly likely to include the contact that turns out
to have the best efficacy with a wide therapeutic win-
dow. Clinical testing was performed at least 4 months
after lead implantation, when the majority of any stun
effect has lapsed16 and the clinical relevance of contact
screening therefore heightened. Thus, the LFP can
serve as a predictive and supportive tool for multicon-
tact lead programming. This is in line with previous
studies showing similar results for the ring contact
electrode,11,13-15 as well as with an intraoperative tri-
al17 and a single, early postoperative case report with
directional stimulation.18
Why should beta power in the LFP predict the clinical
efficacy of stimulation fields of different orientation? It
has been shown that the dorsal part of STN is the most
effective site for STN stimulation in PD,19,20 and that
this is also the focus of beta activity.11-13 Yet, the LFP
cannot afford direct information about the contact spe-
cific therapeutic window, because side effect threshold
depends on the vicinity of the stimulation field to neigh-
boring structures. On the other hand, as current direct-
ed to the dorsal STN is less likely to spread to these
neighboring areas, the prediction of the contact with the
lowest threshold for clinical effect may also explain the
predictive value for the contact with the widest thera-
peutic window.
LFP-Based Programming
If we assume that it takes around 20 minutes to assess
stimulation at each contact, then monopolar contact
review of segmented leads will take around 4 hours (12
segmented contacts). This would be fatiguing for both
clinician and patient, leading to variability in assess-
ments. If only those two segmented contacts that have
the highest beta activity are screened on each side, then
there is approximately a 90% probability of selecting
the contacts that have the lowest effect threshold. This
would only take 80 minutes, reducing assessment time
by approximately two thirds. Moreover, as discussed
FIG. 1. Directional LFPs and relationship between ranked beta activity and clinical efficacy. (A) illustrates the directional DBS lead (Boston Scientific,
Marlborough, MA). Contacts are distributed along four levels. On levels two and three, there are three segmented contacts (level two: contacts 2/3/4;
level three: contacts 5/6/7). (B) shows an example time frequency spectrum from an intraoperative LFP recording (duration, 100 seconds) from the six
directional contacts (2/3/4; 5/6/7) with the patient awake and at rest. The dashed white line marks the beta frequency band (13-35Hz). It shows that
LFP beta activity is not equally distributed across directional contacts. Contact 5 shows the highest beta activity, followed by contact 2, with both con-
tacts 5 and 2 oriented in the same direction. Data from the right hemisphere in subject 3 (for raw data, amplitude-frequency spectrum, and imaging
from the same subject and hemisphere, see Supplementary Fig. 1). (C) illustrates the relationships between normalized beta activity and clinical effica-
cy across the six directional contacts in each hemisphere (H5 hemisphere; n519). The normalized beta amplitude is shown on the x-axis, the clinical
efficacy on the y-axis, and Spearman correlation coefficients are shown on the top of each panel. The best electrophysiological contact (contact with
highest normalized beta activity) is highlighted in black. The red linear regression fit is shown only for illustration purposes. In 15 hemispheres, a posi-
tive relationship between clinical efficacy and normalized beta activity was found (t1854.65; P< 0.001, one-sample t test). In 12 of 19 hemispheres,
the contact with the highest beta activity matched the clinically most effective stimulation contact. Furthermore, in all hemispheres, the contact with
the highest beta activity was localized in the upper-right quadrant, where the clinically more efficient contacts are localized. Clinical efficacy and nor-
malized beta activity are illustrated as ranked values; Supplementary Figure 3 shows the same figure with nonranked values. [Color figure can be
viewed at wileyonlinelibrary.com]
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above, the two segmented contacts with the highest
beta activity are also more likely to have a wider thera-
peutic window. Hence, this method potentially offers a
physiologically based, time-saving approach to the pro-
gramming of directional electrodes.
Limitations
In this investigation, we only studied those sides with
at least two points of upper-limb rigidity and more than
a minimum range of responses to stimulation across
contacts. We also limited the electrophysiological-
clinical comparison to the clinical data acquired during
the monopolar review session, where rigidity was the
only systematically assessed item. However, rigidity is
also the most sensitive clinical sign to DBS.6 These
inclusion criteria were chosen to optimize the clinical
comparison across contacts, and to avoid ceiling and
floor effects. The value of beta activity and of other
LFP features in predicting the best contact for tremor
suppression needs further evaluation.
In addition, we assumed that the monopolar review
in and of itself is predictive of chronic stimulation set-
tings.6,19 Moreover, manual clinical contact testing,
FIG. 2. LFP-based DBS programming. (A) shows the probability of identifying the stimulation contact with the highest clinical efficacy, comparing
the conventional (random) test strategy in blue with the LFP-based test strategy in red (full red line: all hemispheres n5 19, dashed red line: only
hemispheres with clear beta peak n5 12). While for conventional mapping the probability of identifying the most efficient stimulation contact
increases by 0.17 with each contact tested, the LFP-based strategy identifies the most efficient contact with a probability of 0.63 if only the contact
with the highest beta activity is considered, and with a probability of 0.84 if the two contacts with the highest beta activity are considered. By con-
sidering hemispheres with a clear beta peak only, the probability increases up to 0.92 when the two best electrophysiological contacts are consid-
ered. (B) The mean clinical efficacy of the two directional stimulation contacts with the highest beta activity (“Best ephys”) is significantly higher
compared to the clinical efficacy of the remaining directional contacts (“other dir.”). (C) (similar to A) shows the probability of identifying the contact
with the highest therapeutic window by again comparing the conventional (random) test strategy in blue with the LFP-based test strategy in red (full
red line: all hemispheres n519; dashed red line: only hemispheres with clear beta peak n512). While for conventional mapping the probability of
identifying the stimulation contact with the widest therapeutic window increases by 0.17 with each contact tested, the LFP-based strategy identifies
the contact with the widest therapeutic window with a probability of 0.42 if only the contact with the highest beta activity is considered, and with a
probability of 0.74 if the two contacts with the highest beta activity are considered. No relevant difference in the predictive value is found when
exclusively hemispheres with a clear beta peak are considered (dashed red line). (D) The mean TW of the two directional stimulation contacts with
the highest beta activity (“Best ephys”) is significantly higher compared to the therapeutic window of the remaining directional contacts. Values are
mean6SEM; **P< 0.01. [Color figure can be viewed at wileyonlinelibrary.com]
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although the current “gold standard” for determining
the best stimulation contacts, is a subjective method
with some degree of inter-rater variability. Any noise
in the gold-standard estimation will only have served
to degrade the apparent predictive value of the LFP.
Intraoperative time constraints meant that LFPs
could only be recorded for around 2 minutes (with
interindividual variability), and longer recordings
might have been more representative. Importantly, we
also assumed that lead position and orientation did
not change after LFP recording. Furthermore, our data
may have been contaminated by stun effects, which
can be detected as the STN is traversed and lead to
diminished beta power.10
Future Directions and Conclusion
Tools that can assist DBS programming by the clini-
cian or even run fully automatically are desirable in
this era of directional, multicontact leads. This could
streamline the postoperative management of patients,
and free up clinical resources to contend with the
increasing numbers of such patients dictated by grow-
ing experience with this therapy and by the move to
offer DBS earlier during the disease course.21 Never-
theless, the clinical advantage, or lack thereof, of
chronic directional DBS still needs to be definitively
demonstrated.
The method presented is of potential predictive value
with respect to subsequent programming, regardless of
whether microelectrode recordings are used or not in
targeting the STN. In time, optimal contact prediction
might be based on a variety of features. The electro-
physiological approach taken here might be supple-
mented by radiological-anatomical strategies that could
provide more-accurate information about surrounding
structures. However, presently, these are challenging to
implement, given that target structures are small and
image resolution is limited, so that the error rate in
lead localization is not negligible.22
In conclusion, the present study suggests that the
amplitude of subthalamic beta LFP activity is predic-
tive of the most efficient stimulation contact and can
form the basis for a rapid programming tool useful for
multicontact directional DBS leads.
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